3.
Univariate and multivariate survival analysis of GC patients in the whole study series
| Characteristics | n (%) | 5-year OS (%) | Univariate analysis | Multivariate analysis | ||
| χ2 | P | HR (95% CI) | P | |||
| GC, gastric cancer; CA19-9, carbohydrate antigen; LVI, lymphovascular infiltration; CEA, carcinoembryonic antigen; OS, overall survival; HR, hazard ratio; 95% CI, 95% confident interval. | ||||||
| Sex | 1.680 | 0.195 | ||||
| Male | 705 (70.0) | 64.6 | ||||
| Female | 302 (30.0) | 59.9 | ||||
| Age at surgery (year) | 9.434 | 0.002 | 1 (ref) | |||
| <70 | 873 (86.7) | 64.9 | 1.731 (1.311−2.285) | <0.001 | ||
| ≥70 | 134 (13.3) | 51.7 | ||||
| Tumor location | 21.199 | <0.001 | ||||
| Lower one-third | 409 (40.6) | 69.1 | 1 (ref) | |||
| Middle one-third | 242 (24.0) | 63.5 | 1.272 (0.878−1.844) | 0.204 | ||
| Upper one-third | 166 (16.5) | 61.5 | 1.106 (0.710−1.327) | 0.852 | ||
| 2/3 or more | 190 (18.9) | 51.3 | 1.160 (0.778−1.730) | 0.466 | ||
| Tumor size (cm) | 41.781 | <0.001 | ||||
| <5 | 541 (53.7) | 71.9 | 1 (ref) | |||
| ≥5 | 466 (46.3) | 53.1 | 1.013 (0.766−1.339) | 0.929 | ||
| Borrmann type | 90.158 | <0.001 | ||||
| 0 | 157 (15.6) | 90.4 | 1 (ref) | |||
| I | 45 (4.5) | 71.0 | 1.268 (0.504−3.193) | 0.614 | ||
| II | 97 (9.6) | 68.9 | 2.004 (0.912−4.404) | 0.083 | ||
| III | 644 (64.0) | 57.9 | 1.589 (0.734−3.442) | 0.240 | ||
| IV | 64 (6.4) | 34.4 | 2.683 (1.159−6.211) | 0.021 | ||
| Histology | 2.427 | 0.119 | ||||
| Differentiated | 167 (16.6) | 68.2 | ||||
| Undifferentiated | 840 (83.4) | 62.2 | ||||
| TNM stage | 206.154 | <0.001 | ||||
| I | 231 (22.9) | 89.9 | 1 (ref) | |||
| II | 281 (27.9) | 70.6 | 2.220 (1.185−4.161) | 0.013 | ||
| IIIa | 282 (28.0) | 53.7 | 3.353 (1.766−6.366) | <0.001 | ||
| IIIb | 144 (14.3) | 42.4 | 4.029 (2.047−7.929) | <0.001 | ||
| IIIc | 69 (6.9) | 26.1 | 6.644 (3.273−13.490) | <0.001 | ||
| Type of gastrectomy | 27.508 | <0.001 | ||||
| Subtotal | 624 (62.0) | 69.0 | 1 (ref) | |||
| Total | 383 (38.0) | 53.7 | 1.258 (0.935−1.692) | 0.129 | ||
| Extranodal tumor deposits | 147.017 | <0.001 | ||||
| Absent | 708 (70.3) | 73.9 | 1 (ref) | |||
| Present | 299 (29.7) | 37.8 | 1.620 (1.266−2.072) | <0.001 | ||
| LVI | 52.099 | <0.001 | ||||
| Absent | 783 (77.8) | 68.9 | 1 (ref) | |||
| Present | 224 (22.2) | 42.8 | 1.370 (1.094−1.717) | 0.006 | ||
| Preoperative CEA levels | 27.566 | <0.001 | ||||
| Normal | 859 (85.3) | 66.3 | 1 (ref) | |||
| Elevated | 148 (14.7) | 44.9 | 1.166 (0.892−1.524) | 0.262 | ||
| Preoperative CA19-9 levels | 30.112 | <0.001 | ||||
| Normal | 866 (86.0) | 66.3 | 1 (ref) | |||
| Elevated | 141 (14.0) | 44.1 | 1.169 (0.894−1.528) | 0.253 | ||